The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of vorinostat (SAHA), cladribine (2-CdA), and rituximab in previously untreated mantle cell lymphoma: A phase I/II study.
S. E. F. Spurgeon
No relevant relationships to disclose
A. I. Chen
No relevant relationships to disclose
B. Ratterree
No relevant relationships to disclose
C. Okada
Honoraria - Merck
G. Palmbach
No relevant relationships to disclose
K. Diaz
No relevant relationships to disclose
N. Subbiah
No relevant relationships to disclose
C. Capper
No relevant relationships to disclose
E. E. Epner
Honoraria - Merck